Group 1 - On March 3, 2026, Fonda Holdings, a subsidiary of Tiger Med Group, announced the completion of its acquisition of Guanhua Medical, enhancing Fonda's global central laboratory capabilities and service capacity in China and the Asia-Pacific region [1] - Guanhua Medical is a leading clinical research laboratory service provider in China, having supported over 1,500 clinical trials across multiple therapeutic areas, and has extensive experience in regulatory compliance and high-quality laboratory testing services [1] - Following the acquisition, Fonda Holdings aims to expand its central laboratory network in China and improve its comprehensive support for domestic clinical research and multi-regional clinical trials (MRCT) [1] Group 2 - A representative from Fonda Holdings stated that the integration of Guanhua Medical is a significant step in Fonda's global development, aligning with Fonda's commitment to quality and compliance standards [2] - The acquisition is part of Fonda Holdings' ongoing efforts to enhance its global footprint, leveraging a unified quality system and operational standards to improve collaboration between China and the U.S. and accelerate the delivery of innovative drugs to international markets [2] Group 3 - Fonda Holdings is a comprehensive pharmaceutical R&D CRO with established centers in China, North America, and Europe, providing a wide range of services including drug chemistry, pharmacology, DMPK, and clinical research [3] - The company adheres to a "global unified quality system" and has successfully passed over 350 audits from regulatory agencies, including more than 200 from the FDA, over its 25 years of operation [3]